JULY 24: URO TODAY: Metastatic prostate cancer is an attractive target for radio-immunotherapy (RIT), as no effective therapies are available.
This review highlights the most important achievements within the last year in 3-D positron emission tomography (PET)/computed tomography (CT) and RIT. READ MORE>









